Key Performance
More- Earnings Score: N/A
- Momentum Score: 35
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Immuron Double Digit 3Q Sales Growth
Immuron Limited announced Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by growth in Australia (+15%), Canada (+82% quarter-over-quarter), and the USA (+1%). The company attributed growth to increased digital marketing, new retail partnerships, and brand awareness initiatives for its Travelan® product across all regions.
04/17/2026, 6:00 AM • GlobeNewswire
Immuron Reports HY26 Results and Strategic Reset
Immuron Limited reported H1 FY26 global sales of AUD$4.2 million with 5% growth and strong U.S. momentum (+17% YoY). The company raised AUD$7.3 million and announced a strategic reset focusing on partnerships to advance its Travelan® and IMM-529 clinical programs. IMM-124E is eligible for FDA end of Phase 2 meeting, while IMM-529 received FDA IND approval for C. difficile treatment.
02/25/2026, 6:00 AM • GlobeNewswire
Immuron New U.S. Department of Defense Award & Clinical Trial Update
Immuron Limited receives a U.S. Department of Defense subaward to develop oral therapeutics targeting Campylobacter and Shigella, with plans to produce hyper-immune bovine colostrum products for pre-clinical evaluation and potential military use.
12/03/2025, 6:00 AM • GlobeNewswire
Immuron IMM-529 IND approved by FDA
Immuron Limited received FDA approval for its Investigational New Drug (IND) application for IMM-529, a potential treatment for Clostridioides difficile infection. The company plans to initiate a Phase 2 clinical trial in the first half of 2026, targeting up to 60 subjects with first episode or recurrent CDI.
11/05/2025, 6:00 AM • GlobeNewswire
Immuron Announces Clinical Trial Update
Immuron Limited submitted an Investigational New Drug (IND) application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company's Travelan® P2TD study results are delayed until November 2025 due to government shutdown, with potential implications for future dosing strategies.
10/31/2025, 6:00 AM • GlobeNewswire
Immuron Submits IMM-529 IND to FDA
Immuron has submitted an Investigational New Drug (IND) application to the FDA for IMM-529, a potential treatment for Clostridioides difficile infection. The company plans to initiate a Phase 2 clinical trial in 2026, targeting a potential annual revenue of $400M.
10/08/2025, 6:00 AM • GlobeNewswire
Immuron Letter to Shareholders – Projects Update
Immuron Limited provides updates on multiple pharmaceutical development projects, including clinical trials for Travelan®, IMM-529, and ProIBS®, with anticipated milestones in late 2025 and potential market opportunities in traveler's diarrhea and infection treatments.
10/02/2025, 6:00 AM • GlobeNewswire
Immuron partners with InvestorHub
Immuron Limited announced a partnership with InvestorHub to create an interactive digital platform for improved investor communication, with plans to share content about upcoming milestones including FDA submission for IMM-529 and clinical trial results for Travelan®.
08/26/2025, 10:29 PM • GlobeNewswire
Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream
EmergingGrowth.com announced the schedule for its 85th conference featuring presentations from multiple public companies across various sectors on August 20-21, 2025, providing insights into emerging growth companies.
08/20/2025, 7:00 AM • GlobeNewswire
Immuron - FY25 global sales exceed projection, up 49% on prior year
Immuron Limited reported record annual sales of AUD$7.3 million for FY25, representing a 49% growth. The company saw strong performance in Australia and North America, with Travelan® sales increasing across both markets.
07/17/2025, 6:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.